Colorectal hepatic metastasis - current therapeutic approach

European Gastroenterology and Hepatology Review

Volumn 7, Issue 1, 2011, Pages 54-60

  Mayo, Skye C ^a   Pawlik, Timothy M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; Colorectal metastases; Hepatic resection; Liver; Radiofrequency ablation; Surgery

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ARTICLE; ARTIFICIAL EMBOLISM; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORPHOLOGY; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COLORECTAL CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; HUMAN; LAPAROTOMY; LIVER FAILURE; LIVER METASTASIS; LIVER RESECTION; LIVER TOXICITY; METASTASIS RESECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT SAFETY; PATIENT SELECTION; PORTAL VEIN; POSTOPERATIVE COMPLICATION; PREOPERATIVE EVALUATION; PRIMARY TUMOR; PROGNOSIS; RADIOFREQUENCY ABLATION; REOPERATION; RISK ASSESSMENT; SCORING SYSTEM; SURVIVAL TIME;

EID: 79954589265     PISSN: 17583799     EISSN: 17583802     Source Type: Journal    
DOI: None     Document Type: Article

References (103)

1. Parkin DM, Bray F, Ferlay J, Pisani P, Estimating the world cancer burden: Globocan 2000, Int J Cancer, 2001;94(2):153-6.
2. Jemal A, Siegel R, Xu J, Ward E, Cancer statistics, 2010, CA Cancer J Clin, 2010;60(5):277-300.
3. Steele G Jr, Ravikumar TS, Resection of hepatic metastases from colorectal cancer. Biologic perspective, Ann Surg, 1989;210(2):127-38.
4. Geoghegan JG, Scheele J, Treatment of colorectal liver metastases, Br J Surg, 1999;86(2):158-69.
5. Bengtsson G, Carlsson G, Hafstrom L, Jonsson PE, Natural history of patients with untreated liver metastases from colorectal cancer, Am J Surg, 1981;141(5):586-9.
6. Saltz LB, Cox JV, Blanke C, et al., Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group, N Engl J Med, 2000;343(13):905-14.
7. Douillard JY, Cunningham D, Roth AD, et al., Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial, Lancet, 2000;355(9209):1041-7.
8. Fong Y, Fortner J, Sun RL, et al., Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases, Ann Surg, 1999;230(3):309-18, discussion 318-21.
9. Zakaria S, Donohue JH, Que FG, et al., Hepatic resection for colorectal metastases: value for risk scoring systems?, Ann Surg, 2007;246(2):183-91.
10. Minagawa M, Yamamoto J, Kosuge T, et al., Simplified staging system for predicting the prognosis of patients with resectable liver metastasis: development and validation, Arch Surg, 2007;142(3):269-76, discussion 277.
11. Choti MA, Sitzmann JV, Tiburi MF, et al., Trends in long-term survival following liver resection for hepatic colorectal metastases, Ann Surg, 2002;235(6):759-66.
12. Bentrem DJ, Dematteo RP, Blumgart LH, Surgical therapy for metastatic disease to the liver, Annu Rev Med, 2005;56: 139-56.
13. Tsao JI, Loftus JP, Nagorney DM, et al., Trends in morbidity and mortality of hepatic resection for malignancy. A matched comparative analysis, Ann Surg, 1994;220(2): 199-205.
14. Thompson HH, Tompkins RK, Longmire WP Jr, Major hepatic resection. A 25-year experience, Ann Surg, 1983;197(4): 375-88.
15. Bozzetti F, Gennari L, Regalia E, et al., Morbidity and mortality after surgical resection of liver tumors. Analysis of 229 cases, Hepatogastroenterology, 1992;39(3):237-41.
16. Taylor M, Forster J, Langer B, et al., A study of prognostic factors for hepatic resection for colorectal metastases, Am J Surg, 1997;173(6):467-71.
17. Capussotti L, Polastri R, Operative risks of major hepatic resections, Hepatogastroenterology, 1998;45(19):184-90.
18. Asiyanbola B, Chang D, Gleisner AL, et al., Operative mortality after hepatic resection: are literature-based rates broadly applicable?, J Gastrointest Surg, 2008;12(5):842-51.
19. Kamel IR, Choti MA, Horton KM, et al., Surgically staged focal liver lesions: accuracy and reproducibility of dual-phase helical CT for detection and characterization, Radiology, 2003;227(3):752-7.
20. Bipat S, van Leeuwen MS, Comans EF, et al., Colorectal liver metastases: CT, MR imaging, and PET for diagnosis - meta-analysis, Radiology, 2005;237(1):123-31.
21. Kinkel K, Lu Y, Both M, et al., Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis, Radiology, 2002;224(3):748-56.
22. Oudkerk M, van den Heuvel AG, Wielopolski PA, et al., Hepatic lesions: detection with ferumoxide-enhanced T1-weighted MR imaging, Radiology, 1997;203(2):449-56.
23. van Etten B, van der Sijp J, Kruyt R, et al., Ferumoxide-enhanced magnetic resonance imaging techniques in pre-operative assessment for colorectal liver metastases, Eur J Surg Oncol, 2002;28(6):645-51.
24. Huebner RH, Park KC, Shepherd JE, et al., A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer, J Nucl Med, 2000;41(7):1177-89.
25. Pawlik TM, Assumpcao L, Vossen JA, et al., Trends in Nontherapeutic Laparotomy Rates in Patients Undergoing Surgical Therapy for Hepatic Colorectal Metastases, Ann Surg Oncol, 2009;16(2):371-8.
26. Joyce DL, Wahl RL, Patel PV, et al., Preoperative positron emission tomography to evaluate potentially resectable hepatic colorectal metastases, Arch Surg, 2006;141(12): 1220-6, discussion 1227.
27. Charnsangavej C, Clary B, Fong Y, et al., Selection of patients for resection of hepatic colorectal metastases: expert consensus statement, Ann Surg Oncol, 2006;13(10):1261-8.
28. Halkar RK, Toro JR, Lim EH, et al., Role of FDG-PET in the Pre-Operative Evaluation of Surgical Resection of Hepatic Metastases from Colorectal Cancer, Clin Positron Imaging, 1999;2(6):335.
29. Lonneux M, Reffad AM, Detry R, et al., FDG-PET improves the staging and selection of patients with recurrent colorectal cancer, Eur J Nucl Med Mol Imaging, 2002;29(7): 915-21.
30. Scheele J, Stangl R, Altendorf-Hofmann A, Gall FP, Indicators of prognosis after hepatic resection for colorectal secondaries, Surgery, 1991;110(1):13-29.
31. Domont J, Pawlik TM, Boige V, et al., Catalytic subunit of human telomerase reverse transcriptase is an independent predictor of survival in patients undergoing curative resection of hepatic colorectal metastases: a multicenter analysis, J Clin Oncol, 2005;23(13):3086-93.
32. Cady B, Jenkins RL, Steele GD, Jr, et al., Surgical margin in hepatic resection for colorectal metastasis: a critical and improvable determinant of outcome, Ann Surg, 1998;227(4): 566-71.
33. Pawlik TM, Scoggins CR, Zorzi D, et al., Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases, Ann Surg, 2005;241(5):715-22, discussion 722-4.
34. Figueras J, Burdio F, Ramos E, et al., Effect of subcentimeter nonpositive resection margin on hepatic recurrence in patients undergoing hepatectomy for colorectal liver metastases. Evidences from 663 liver resections, Ann Oncol, 2007;18(7):1190-5.
35. Are C, Gonen M, Zazzali K, et al., The impact of margins on outcome after hepatic resection for colorectal metastasis, Ann Surg, 2007;246(2):295-300.
36. Altendorf-Hofmann A, Scheele J, A critical review of the major indicators of prognosis after resection of hepatic metastases from colorectal carcinoma, Surg Oncol Clin N Am, 2003;12(1):165-92, xi.
37. Jenkins LT, Millikan KW, Bines SD, et al., Hepatic resection for metastatic colorectal cancer, Am Surg, 1997;63(7):605-10.
38. Kokudo N, Imamura H, Sugawara Y, et al., Surgery for multiple hepatic colorectal metastases, J Hepatobiliary Pancreat Surg, 2004;11(2):84-91.
39. Weber SM, Jarnagin WR, DeMatteo RP, et al., Survival after resection of multiple hepatic colorectal metastases, Ann Surg Oncol, 2000;7(9):643-50.
40. Bolton JS, Fuhrman GM, Survival after resection of multiple bilobar hepatic metastases from colorectal carcinoma, Ann Surg, 2000;231(5):743-51.
41. Yan TD, Padang R, Morris DL, Longterm results and prognostic indicators after cryotherapy and hepatic arterial chemotherapy with or without resection for colorectal liver metastases in 224 patients: longterm survival can be achieved in patients with multiple bilateral liver metastases, J Am Coll Surg, 2006;202(1):100-11.
42. Imamura H, Seyama Y, Kokudo N, et al., Single and multiple resections of multiple hepatic metastases of colorectal origin, Surgery, 2004;135(5):508-17.
43. Malik HZ, Hamady ZZ, Adair R, et al., Prognostic influence of multiple hepatic metastases from colorectal cancer, Eur J Surg Oncol, 2007;33(4):468-73.
44. Shimada H, Tanaka K, Masui H, et al., Results of surgical treatment for multiple (> or =5 nodules) bi-lobar hepatic metastases from colorectal cancer, Langenbecks Arch Surg, 2004;389(2):114-21.
45. Takahashi S, Nagai K, Saito N, et al., Multiple resections for hepatic and pulmonary metastases of colorectal carcinoma, Jpn J Clin Oncol, 2007;37(3):186-92.
46. Jaeck D, Pessaux P, Bilobar colorectal liver metastases: treatment options, Surg Oncol Clin N Am, 2008;17(3):553-68, ix.
47. Pawlik TM, Abdalla EK, Ellis LM, et al., Debunking dogma: surgery for four or more colorectal liver metastases is justified, J Gastrointest Surg, 2006;10(2):240-8.
48. Pawlik TM, Schulick RD, Choti MA. Expanding criteria for resectability of colorectal liver metastases, Oncologist, 2008;13(1):51-64.
49. Pawlik TM, Choti MA, Surgical therapy for colorectal metastases to the liver, J Gastrointest Surg, 2007;11(8): 1057-77.
50. Vauthey JN, Pawlik TM, Abdalla EK, et al., Is extended hepatectomy for hepatobiliary malignancy justified?, Ann Surg, 2004;239(5):722-30, discussion 730-32.
51. Abdalla EK, Denys A, Chevalier P, et al., Total and segmental liver volume variations: implications for liver surgery, Surgery, 2004;135(4):404-10.
52. Abdalla EK, Barnett CC, Doherty D, et al., Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization, Arch Surg, 2002;137(6):675-80, discussion 680-1.
53. Vauthey JN, Abdalla EK, Doherty DA, et al., Body surface area and body weight predict total liver volume in Western adults, Liver Transpl, 2002;8(3):233-40.
54. Vauthey JN, Chaoui A, Do KA, et al., Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations, Surgery, 2000;127(5):512-9.
55. Farges O, Belghiti J, Kianmanesh R, et al., Portal vein embolization before right hepatectomy: prospective clinical trial, Ann Surg, 2003;237(2):208-17.
56. Elias D, Goharin A, El Otmany A, et al., Usefulness of intraoperative radiofrequency thermoablation of liver tumours associated or not with hepatectomy, Eur J Surg Oncol, 2000;26(8):763-9.
57. Curley SA, Izzo F, Abdalla E, Vauthey JN, Surgical treatment of colorectal cancer metastasis, Cancer Metastasis Rev, 2004;23(1-2):165-82.
58. McGahan JP, Brock JM, Tesluk H, et al., Hepatic ablation with use of radio-frequency electrocautery in the animal model, J Vasc Interv Radiol, 1992;3(2):291-7.
59. Pawlik TM, Izzo F, Cohen DS, et al., Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients, Ann Surg Oncol, 2003;10(9):1059-69.
60. Gleisner AL, Choti MA, Assumpcao L, et al., Colorectal liver metastases: recurrence and survival following hepatic resection, radiofrequency ablation, and combined resection-radiofrequency ablation, Arch Surg, 2008;143(12):1204-12.
61. Abdalla EK, Vauthey JN, Ellis LM, et al., Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases, Ann Surg, 2004;239(6):818-25, discussion 825-7.
62. Adam R, Laurent A, Azoulay D, et al., Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors, Ann Surg, 2000;232(6):777-85.
63. Jaeck D, Bachellier P, Nakano H, et al., One or two-stage hepatectomy combined with portal vein embolization for initially nonresectable colorectal liver metastases, Am J Surg, 2003;185(3):221-9.
64. Jaeck D, Oussoultzoglou E, Rosso E, et al., A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases, Ann Surg, 2004;240(6):1037-49, discussion 1049-51.
65. Reddy SK, Pawlik TM, Zorzi D, et al., Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis, Ann Surg Oncol, 2007;14(12):3481-91.
66. Elias D, Baton O, Sideris L, et al., Hepatectomy plus intraoperative radiofrequency ablation and chemotherapy to treat technically unresectable multiple colorectal liver metastases, J Surg Oncol, 2005;90(1):36-42.
67. Elias D, De Baere T, Roche A, et al., During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma, Br J Surg, 1999;86(6):784-8.
68. Kianmanesh R, Farges O, Abdalla EK, et al., Right portal vein ligation: a new planned two-step all-surgical approach for complete resection of primary gastrointestinal tumors with multiple bilateral liver metastases, J Am Coll Surg, 2003;197(1): 164-70.
69. Broering DC, Hillert C, Krupski G, et al., Portal vein embolization vs. portal vein ligation for induction of hypertrophy of the future liver remnant, J Gastrointest Surg, 2002;6(6):905-13, discussion 913.
70. Aussilhou B, Lesurtel M, Sauvanet A, et al., Right portal vein ligation is as efficient as portal vein embolization to induce hypertrophy of the left liver remnant, J Gastrointest Surg, 2008;12(2):297-303.
71. Chun YS, Ribero D, Abdalla EK, et al., Comparison of two methods of future liver remnant volume measurement, J Gastrointest Surg, 2008;12(1):123-8.
72. Arteaga CL, The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia, J Clin Oncol, 2001;19(Suppl. 18): 32S-40S.
73. Tol J, Koopman M, Cats A, et al., Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer, N Engl J Med, 2009;360(6):563-72.
74. Nordlinger B, Sorbye H, Glimelius B, et al., Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial, Lancet, 2008;371(9617):1007-16.
75. Adam R, Avisar E, Ariche A, et al., Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal, Ann Surg Oncol, 2001;8(4):347-53.
76. Adam R, Delvart V, Pascal G, et al., Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival, Ann Surg, 2004;240(4):644-57, discussion 657-8.
77. Bismuth H, Adam R, Levi F, et al., Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy, Ann Surg, 1996;224(4):509-20, discussion 520-2.
78. Rivoire M, De Cian F, Meeus P, et al., Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma, Cancer, 2002;95(11):2283-92.
79. Vauthey JN, Pawlik TM, Ribero D, et al., Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases, J Clin Oncol, 2006;24(13):2065-72.
80. Karoui M, Penna C, Amin-Hashem M, et al., Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases, Ann Surg, 2006;243(1):1-7.
81. Fowler WC, Eisenberg BL, Hoffman JP, Hepatic resection following systemic chemotherapy for metastatic colorectal carcinoma, J Surg Oncol, 1992;51(2):122-5.
82. Wein A, Riedel C, Kockerling F, et al., Impact of surgery on survival in palliative patients with metastatic colorectal cancer after first line treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and folinic acid, Ann Oncol, 2001;12(12):1721-7.
83. Cady B, Monson DO, Swinton NW, Survival of patients after colonic resection for carcinoma with simultaneous liver metastases, Surg Gynecol Obstet, 1970;131(4):697-700.
84. Blumgart LH, Allison DJ, Resection and embolization in the management of secondary hepatic tumors, World J Surg, 1982;6(1):32-45.
85. Jatzko G, Wette V, Muller M, et al., Simultaneous resection of colorectal carcinoma and synchronous liver metastases in a district hospital, Int J Colorectal Dis, 1991;6(2):111-4.
86. Schlag P, Hohenberger P, Herfarth C, Resection of liver metastases in colorectal cancer - competitive analysis of treatment results in synchronous versus metachronous metastases, Eur J Surg Oncol, 1990;16(4):360-5.
87. Elias D, Detroz B, Lasser P, et al., Is simultaneous hepatectomy and intestinal anastomosis safe?, Am J Surg, 1995;169(2):254-60.
88. Fujita S, Akasu T, Moriya Y, Resection of synchronous liver metastases from colorectal cancer, Jpn J Clin Oncol, 2000;30(1):7-11.
89. Chua HK, Sondenaa K, Tsiotos GG, et al., Concurrent vs. staged colectomy and hepatectomy for primary colorectal cancer with synchronous hepatic metastases, Dis Colon Rectum, 2004;47(8):1310-6.
90. Benoist S, Pautrat K, Mitry E, et al., Treatment strategy for patients with colorectal cancer and synchronous irresectable liver metastases, Br J Surg, 2005;92(9):1155-60.
91. Lyass S, Zamir G, Matot I, et al., Combined colon and hepatic resection for synchronous colorectal liver metastases, J Surg Oncol, 2001;78(1):17-21.
92. Martin R, Paty P, Fong Y, et al., Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis, J Am Coll Surg, 2003;197(2):233-41, discussion 241-2.
93. Bozzetti F, Doci R, Bignami P, et al., Patterns of failure following surgical resection of colorectal cancer liver metastases. Rationale for a multimodal approach, Ann Surg, 1987;205(3):264-70.
94. Ekberg H, Tranberg KG, Andersson R, et al., Pattern of recurrence in liver resection for colorectal secondaries, World J Surg, 1987;11(4):541-7.
95. Lange JF, Leese T, Castaing D, Bismuth H, Repeat hepatectomy for recurrent malignant tumors of the liver, Surg Gynecol Obstet, 1989;169(2):119-26.
96. Stone MD, Cady B, Jenkins RL, et al., Surgical therapy for recurrent liver metastases from colorectal cancer, Arch Surg, 1990;125(6):718-21, discussion 722.
97. Adam R, Bismuth H, Castaing D, et al., Repeat hepatectomy for colorectal liver metastases, Ann Surg, 1997;225(1):51-60, discussion 60-2.
98. Bismuth H, Adam R, Navarro F, et al., Re-resection for colorectal liver metastasis, Surg Oncol Clin N Am, 1996;5(2): 353-64.
99. Scheele J, Stang R, Altendorf-Hofmann A, Paul M, Resection of colorectal liver metastases, World J Surg, 1995;19(1):59-71.
100. Fernandez FG, Drebin JA, Linehan DC, et al., Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET), Ann Surg, 2004;240(3):438-47.
101. Goldberg RM, Sargent DJ, Morton RF, et al., A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer, J Clin Oncol, 2004;22(1):23-30.
102. Hurwitz H, Fehrenbacher L, Novotny W, et al., Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med, 2004;350(23): 2335-42.
103. Cunningham D, Humblet Y, Siena S, et al., Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer, N Engl J Med, 2004;351(4):337-45.